« Previous
Next »
Journal of the American Academy of Dermatology
Volume 60, Issue 4
, Pages
565-573
, April 2009
A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa
To access this article, please choose from the options below
Supported by an unrestricted grant from Amgen and grant K23AR051125 from the National Institute of Arthritis, Musculoskeletal, and Skin Diseases (Dr Gelfand).
Disclosure: Dr Gelfand has received grant support from Amgen and Centocor, and is a consultant to Amgen, Abbott, Centocor, Genentech, and Astellas. Drs Lee, Treat, Sciacca-Kirby, Chachkin, Leyden, and Vittorio, Ms Dommasch, Ms Williams, and Mr Shin have no conflicts of interest to declare.
PII: S0190-9622(08)02470-5
doi: 10.1016/j.jaad.2008.11.898
© 2008 American Academy of Dermatology, Inc. Published by Elsevier Inc All rights reserved.
« Previous
Next »
Journal of the American Academy of Dermatology
Volume 60, Issue 4
, Pages
565-573
, April 2009
